The U of Colorado-Boulder NR trial results were released last week and showed promising results for those taking 1,000 mg of NR (Nicotinamide Riboside), a derivative of vitamin B3, a day for six weeks. (The Elysium study released last December suggests little increase in NAD+ levels above 500 mg a day, beyond eight weeks.)
First, it looks like NR improved flexiblity in the aurota among healthy non-obese people. Second, NR lowered the systoic blood pressure by an average of 10 points among those with pre-hypertension but not in adults aged 55 to 79 with normal blood pressure.
Chris Martens at the U of Delaware stated: “What this paper provides us with is a really good stepping stone for future work.”
The U of Colorado article also mentions that Martens is preparing a new trial on older adults with mild cognitive impairment.